Befekadu Asfaw

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3961422/publications.pdf Version: 2024-02-01



REFERADU ASEAN

#	Article	IF	CITATIONS
1	Link between a novel human gammaD-crystallin allele and a unique cataract phenotype explained by protein crystallography. Human Molecular Genetics, 2000, 9, 1779-1786.	2.9	133
2	A novel mutation in the coding region of the prosaposin gene leads to a complete deficiency of prosaposin and saposins, and is associated with a complex sphingolipidosis dominated by lactosylceramide accumulation. Human Molecular Genetics, 2001, 10, 927-940.	2.9	100
3	Acid sphingomyelinase deficiency. Phenotype variability with prevalence of intermediate phenotype in a series of twenty-five Czech and Slovak patients. A multi-approach study. Journal of Inherited Metabolic Disease, 2005, 28, 203-227.	3.6	85
4	Prosaposin deficiency and saposin B deficiency (activatorâ€deficient metachromatic leukodystrophy): Report on two patients detected by analysis of urinary sphingolipids and carrying novel PSAP gene mutations. American Journal of Medical Genetics, Part A, 2009, 149A, 613-621.	1.2	79
5	Benzenediazonium Ion Derived from Sudan I Forms an 8-(Phenylazo)guanine Adduct in DNA. Chemical Research in Toxicology, 1995, 8, 489-498.	3.3	57
6	Quantitation of plasmatic lysosphingomyelin and lysosphingomyelin-509 for differential screening of Niemann-Pick A/B and C diseases. Analytical Biochemistry, 2017, 525, 73-77.	2.4	49
7	The first identification of the benzenediazonium ion formation from a non-aminoazo dye, 1-phenylazo-2-hydroxynaphthalene (Sudan I) by microsomes of rat livers. Cancer Letters, 1988, 40, 319-326.	7.2	43
8	A new way to carcinogenicity of azo dyes: The benzenediazonium ion formed from a non-aminoazo dye, 1-phenylazo-2-hydroxynaphthalene(Sudan I) by microsomal enzymes binds to deoxyguanosine residues of DNA. Cancer Letters, 1988, 40, 327-333.	7.2	34
9	Determination of Urinary Sulfatides and Other Lipids by Combination of Reversed-Phase and Thin-Layer Chromatographies. Analytical Biochemistry, 1999, 269, 304-311.	2.4	32
10	Defects in degradation of blood group A and B glycosphingolipids in Schindler and Fabry diseases. Journal of Lipid Research, 2002, 43, 1096-1104.	4.2	30
11	Replacement of α-galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 452, 651-665.	2.8	29
12	Mucolipidosis IV: Report of a Case with Ocular Restricted Phenotype Caused by Leaky Splice Mutation. American Journal of Ophthalmology, 2007, 143, 663-671.e2.	3.3	24
13	Direct tandem mass spectrometric profiling of sulfatides in dry urinary samples for screening of metachromatic leukodystrophy. Clinica Chimica Acta, 2013, 425, 153-159.	1.1	16
14	Fabry disease: renal sphingolipid distribution in the α-Gal A knockout mouse model by mass spectrometric and immunohistochemical imaging. Analytical and Bioanalytical Chemistry, 2015, 407, 2283-2291.	3.7	16
15	Oxidation of Azo Dyes by Peroxidase: Additional Evidence of a One-Electron Mechanism of Oxidation of Dimethylaminoazobenzene and Sudan I (Solvent Yellow 14). Collection of Czechoslovak Chemical Communications, 1996, 61, 962-972.	1.0	15
16	Activation of carcinogens by peroxidase Horseradish peroxidase-mediated formation of benzenediazonium ion from a non-aminoazo dye, 1-phenylazo-2-hydroxynaphthalene (Sudan I) and its binding to DNA. FEBS Letters, 1988, 232, 387-390.	2.8	14
17	Degradation of blood group A glycolipid A-6-2 by normal and mutant human skin fibroblasts. Journal of Lipid Research, 1998, 39, 1768-1780.	4.2	14
18	Semisynthesis of C17:0 isoforms of sulphatide and glucosylceramide using immobilised sphingolipid ceramide N-deacylase for application in analytical mass spectrometry. Rapid Communications in Mass Spectrometry, 2010, 24, 2393-2399.	1.5	12

Befekadu Asfaw

#	Article	IF	CITATIONS
19	Lactosylceramide in lysosomal storage disorders. A comparative immunohistochemical and biochemical study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 447, 31-44.	2.8	11
20	Tandem Mass Spectrometry of Sphingolipids. Advances in Clinical Chemistry, 2016, 77, 177-219.	3.7	5
21	Specific storage of glycoconjugates with terminal α-galactosyl moieties in the exocrine pancreas of Fabry disease patients with blood group B. Glycobiology, 2018, 28, 382-391.	2.5	5
22	Transcript, protein, metabolite and cellular studies in skin fibroblasts demonstrate variable pathogenic impacts of NPC1 mutations. Orphanet Journal of Rare Diseases, 2020, 15, 85.	2.7	5
23	Identification of 1-(3,4-Dihydroxyphenylazo)-2-hydroxynaphthalene as the Product of Oxidation of 1-Phenylazo-2-hydroxynaphthalene (Sudan I, Solvent Yellow 14) by Rat Liver Microsomes. Collection of Czechoslovak Chemical Communications, 1994, 59, 2727-2733.	1.0	5
24	Ultrastructural and functional abnormalities of mitochondria in cultivated fibroblasts from α-mannosidosis patients. Biologia (Poland), 2009, 64, 394-401.	1.5	3
25	Ce(IV)-mediated formation of benzenediazonium ion from a non-aminoazo dye, 1-phenylazo-2-hydroxy-naphthalene (Sudan I) and its binding to DNA. Collection of Czechoslovak Chemical Communications, 1989, 54, 2021-2026.	1.0	0
26	Loading of cell cultures with cholesterolâ€dextran particles as a new functional test for Niemann–Pick type C disease. Journal of Inherited Metabolic Disease, 2022, , .	3.6	0